刘立明,周力,李婷颖,刘太阳,余劲松,杨杰
LIU Liming,ZHOU Li,LI Tingying,LIU Taiyang,YU Jinsong,YANG Jie

• 1:保定市第一中心医院内窥镜室
• 2:贵州医科大学附院消化内科
• 3:贵州医科大学

摘要(Abstract)：

目的:探讨肝硬化门脉高压性胃病(PHG)患者血清中胃蛋白酶原Ⅰ与Ⅱ的水平变化。方法:46例肝硬化患者,经胃镜评价分为PHG组(n=17)及非PHG组(n=29),同期健康体检者20例作为对照组;3组受检者于就诊或体检时采集空腹静脉血,采用ELISA法检测血清胃蛋白酶原Ⅰ(PGⅠ)和PGⅡ含量,计算PGⅠ/PGⅡ比值(PGR)。结果:PHG组和对照组血清PGⅠ水平低于非PHG组,差异有统计学意义(P<0.05),而PHG组与对照组比较,差异无统计学意义(P>0.05);PHG组和非PHG组的PGⅡ水平高于对照组,差异有统计学意义(P<0.05),而PHG组和非PHG组比较,差异无统计学意义(P>0.05);3组PGR比较,PHG组<非PHG组<对照组,差异有统计学意义(P<0.05)。结论:肝硬化患者血清PGⅠ水平和PGR值降低可预示PHG的发生。
Objective: To investigate the change of serum pepsinogen I and pepsinogen II level in patients with liver cirrhosis portal hypertensive gastropathy( PHG). Methods: 46 patients with liver cirrhosis were divided into PHG group( n = 17) and non-PHG group( n = 29),and 20 healthy volunteers as control group. Fasting venous blood of three groups were collected while treatment or physical check,adopting ELISA assay to detect PG I and PG II content and calculating PG I/PG II ratio( PGR). Results: The level of serum PGI in the PHG group was lower than that of non-PHG group,differences were statistically significant( P < 0. 05); PHG group and control group comparison showed no statistically difference( P > 0. 05). PG II level of PHG group and non-PHG group were higher than that of control group,differences were statistically significant( P < 0. 05); the level of PGⅡ showed no difference between the PHG group and non-PHG group( P > 0. 05); PGR comparison of three groups showed that PHG group < non-PHG group < control group,differences were statistically significant( P < 0. 05). Conclusion: Lowered level of serum PGI may predict the development of PHG in liver cirrhosis.

关键词(KeyWords)： 肝硬化;高血压,门脉;胃镜检查;胃黏膜;胃蛋白酶原
cirrhosis;hypertension,portal;gastroscopy;gastric mucosa;pepsinogen

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技厅科技计划项目[黔科合LG字(2012)009]

作者(Author): 刘立明,周力,李婷颖,刘太阳,余劲松,杨杰
LIU Liming,ZHOU Li,LI Tingying,LIU Taiyang,YU Jinsong,YANG Jie

DOI: 10.19367/j.cnki.1000-2707.2017.12.018

参考文献(References)：

• [1]Hanafy EI,Hawary AT.Efficacy of argon plasma coagulation in the management of portal hypertensive gastropathy[J].Endosc Int Open,2016(10):1057-1062.
• [2]Patwardhan VR,Cardenas A.Review article:the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis[J].Aliment Pharmacol Ther,2014(4):354-362.
• [3]Ichinose M,Miki K,Furihata C,et al.Radioimmunoassay of groupⅡpepsinogen in human serum[J].Clin Chim Acta,1982(1):61-69.
• [4]Ichinose M,Miki K,Furihata C,et al.Radioimmunoassay of serum groupⅠand groupⅡpepsinogens in normal controls and patients with various disorders[J].Clin Chim Acta,1982(2):183-191.
• [5]Begum A,Baten MA,Begum Z,et al.Role of serum pepsinogenⅠandⅡratio in screening of gastric carcinoma[J].Mymensingh Med J,2017(3):628-634.
• [6]Cho JH,Jeon SR,Kim HG,et al.The serum pepsinogen levels for risk assessment of gastric neoplasms:New proposal from a case-control study in Korea[J].Medicine(Baltimore).2017(29):e7603.
• [7]Kotachi T,Ito M,Yoshihara M,et al.Serological evaluation of gastric cancer risk based on pepsinogen and helicobacter pylori antibody:relationship to endoscopic findings[J].Digestion,2017(4):314-318.
• [8]Schuppan D,Afdhal NH.Liver cirrhosis[J].Lancet,2008(9615):838-851.
• [9]Mc Cormack TT,Sima J,Eyre BI,et al.Gastric lesions in portal hypertension:inflammatory gastritis or congestive gastropathy[J].Gut,1985(11):1226-1232.
• [10]Lubel JS,Angus PW.Modern management of portal hypertension[J].Intern Med J,2005(1):45-49.
• [11]Samonakis DN,Triantos CK,Thalheimer U,et al.Management of portal hypertension[J].Postgrad Med J,2004(949):634-641.
• [12]Draghia A,Draghia F,Coman L.The gastric mucosa in portal hypertension:structural and ultrastructural observations[J].Romanian Journal of Morphology and Embryology,2010(2):271-275.
• [13]Onuigbo MA,Agbasi N,Achebe J,et al.Pleuritic chest pain from portal hypertensive gastropathy in ESRD patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis[J].J Renal Inj Prev,2017(1):48-52.
• [14]Miftahussurur M,Nusi IA,Akil F,et al.Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia[J].PLo S One,2017(5):e0176203.
• [15]Quintero E,Pique JM,Bombi JA,et al.Gastric mucosal vascular ectasias causing bleeding in cirrhosis.A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I[J].Gastroenterology,1987(5):1054-1061.
• [16]王丹,何锐,何媛,等.门脉高压性胃病患者血清胃蛋白酶原检测的意义[J].实用肝脏病杂志,2016(1):94-95.
• [17]曹华,方传华,陈佳婕,等.血清胃蛋白酶原水平变化对肝硬化患者胃黏膜功能的评估价值[J].标记免疫分析与临床,2016(11):1286-1287,1326.
• [18]刘立明,杨杰,周力,等.胃泌素、胃蛋白酶原在肝硬化患者中表达的变化及与肝损伤的相关性[J].贵阳医学院学报,2016(3):116-119.
• [19]Ten Kate RW,Pals G,Eriksson AW,et al.The renal metabolism of pepsinogen A and C in man[J].Clinical nephrology,1989(2):103-106.
• [20]Mandhwani R,Hanif FM,Ul Haque MM,et al.Noninvasive clinical predictors of portal hypertensive gastropathy in patients with liver cirrhosis[J].J Transl Int Med,2017(3):169-173.
• [21]刘立明,周力,杨杰,等.肝硬化胃肌电活动紊乱类型及发生原因初探[J].贵阳医学院学报,2014(2):180-182.

文章评论(Comment)：